LBA47 Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs)
Alexander Stratigos(National and Kapodistrian University of Athens), M.G. Fury(Regeneron (United States)), Michael R. Migden(The University of Texas MD Anderson Cancer Center), Karl D. Lewis(University of Colorado Denver), S. Li(Regeneron (United States)), Claas Ulrich(Charité - Universitätsmedizin Berlin), Axel Hauschild(University Hospital Schleswig-Holstein), Anne Lynn S. Chang(Stanford University), Lisa Licitra(University of Milan), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Nicole Basset‐Séguin(Inserm), Stéphane Dalle(Hospices Civils de Lyon), Reinhard Dummer(University Hospital of Zurich), Martin Kaatz(Klinikum Chemnitz), Caroline Robert(Université Paris-Sud), Almudena Fernández(Hospital Universitario Virgen Macarena), Aleksandar Sekulić(The University of Texas MD Anderson Cancer Center), Ketty Peris(Università Cattolica del Sacro Cuore), Taylor Bowler(Regeneron (United States)), Oliver Bechter(Universitair Ziekenhuis Leuven)
Cited by 14
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k